Table 1.
Baseline patient characteristics
| Characteristic | Total (n = 241) |
|---|---|
| Age, years | |
| Median (IQR) | 68 (61-72) |
| Sex, n (%) | |
| Male | 177 (73.4) |
| Female | 64 (26.6) |
| ECOG PS, n (%) | |
| 0 | 98 (40.7) |
| 1 | 113 (46.9) |
| 2 | 20 (8.3) |
| Unknown | 10 (4.1) |
| ICI plus platinum doublet, n (%) | |
| Pembrolizumab + CBDCA + PEM | 119 (49.4) |
| Pembrolizumab + CBDCA + nab-PTX | 52 (21.6) |
| Pembrolizumab + CDDP + PEM | 18 (7.5) |
| Pembrolizumab + CBDCA + PTX ± bevacizumab | 6 (2.5) |
| Atezolizumab + CBDCA + PTX ± bevacizumab | 25 (10.4) |
| Atezolizumab + CBDCA + nab-PTX | 19 (7.9) |
| Atezolizumab + CBDCA + PEM | 1 (0.4) |
| Atezolizumab + CDDP + PEM | 1 (0.4) |
| Baseline concomitant medications, n (%) | |
| Corticosteroidsa | 10 (4.1) |
| Antibiotics | 59 (24.5) |
| PPIs | 87 (36.1) |
| NSAIDs | 83 (34.4) |
| Metformin | 14 (5.8) |
| Fibrates | 8 (3.3) |
| Statins | 46 (19.1) |
| Baseline peripheral blood counts (cells/mm3), median (IQR) | |
| Absolute neutrophil count | 4846 (3694-6699) |
| Absolute lymphocyte count | 1303 (889-1687) |
| Platelet count | 275000 (225500-351000) |
| Absolute monocyte count | 483 (338-656) |
| NLR, median (IQR) | 3.89 (2.70-5.87) |
| PLR, median (IQR) | 230.8 (158.4-329.2) |
| LMR, median (IQR) | 2.52 (1.78-3.78) |
a Dose ≥10 mg prednisolone equivalent per day and cancer-related use
Abbreviations: IQR: interquartile range; ECOG PS: Eastern Cooperative Oncology Group performance status; ICI: immune checkpoint inhibitor; CBDCA: carboplatin; PEM: pemetrexed; nab-PTX: albumin-binding paclitaxel; CDDP: cisplatin; PTX: paclitaxel; PPIs: proton pump inhibitors; NSAIDs: non-steroidal anti-inflammatory drugs; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio